Comparative Pharmacology
Head-to-head clinical analysis: VICOPRIN versus ZYDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VICOPRIN versus ZYDONE.
VICOPRIN vs ZYDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VICOPRIN (hydrocodone/acetaminophen) combines a mu-opioid receptor agonist (hydrocodone) that inhibits ascending pain pathways and alters pain perception, with an analgesic and antipyretic (acetaminophen) that inhibits cyclooxygenase (COX) and central prostaglandin synthesis.
Hydrocodone is a mu-opioid receptor agonist; acetaminophen produces analgesia via central COX inhibition and activation of descending serotonergic pathways.
1 to 2 tablets (each containing 7.5 mg hydrocodone bitartrate and 200 mg ibuprofen) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
Oral: 1 to 2 tablets every 4 to 6 hours as needed for pain. Each tablet contains hydrocodone bitartrate 5 mg and acetaminophen 500 mg (Zydone 5/500). Maximum acetaminophen dose: 4000 mg/day (8 tablets).
None Documented
None Documented
Hydrocodone: 3.8-6.0 hours in adults; acetaminophen: 2.0-4.0 hours. Clinically, Vicoprofen (hydrocodone/ibuprofen) has an effective half-life of ~4-6 hours for hydrocodone; ibuprofen half-life is 2-4 hours.
Terminal elimination half-life of hydrocodone is 3.8-4.5 hours in healthy adults; prolonged in elderly or hepatic impairment (up to 6-8 hours). Clinical context: dosing interval typically every 4-6 hours, adjusted for renal/hepatic insufficiency.
Renal excretion of metabolites (hydrocodone: ~60% as conjugates; acetaminophen: ~85-90% as glucuronide and sulfate conjugates). Biliary/fecal elimination accounts for <5%.
Approximately 60% of hydrocodone and its metabolites are excreted renally as glucuronide conjugates; ~10% as norhydrocodone, hydromorphone, and other metabolites. Fecal excretion accounts for less than 5%. Total renal elimination: ~65-70%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic